OSE Immuno

OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant

05 6 2024 01:30:00 提供 Nasdaq GlobeNewswire

OSE Immunotherapeutics Provides Business and Corporate Update

30 5 2024 12:15:00 提供 Nasdaq GlobeNewswire

OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases

22 5 2024 01:30:00 提供 Nasdaq GlobeNewswire

OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective

16 4 2024 12:00:00 提供 Nasdaq GlobeNewswire

OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer

10 4 2024 12:00:00 提供 Nasdaq GlobeNewswire

OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology

02 4 2024 01:30:00 提供 Nasdaq GlobeNewswire

OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update

27 3 2024 13:00:00 提供 Nasdaq GlobeNewswire